Skip to main content
Journal ArticleOPEN ACCESS

SARS-CoV-2 spike therapeutic antibodies in the age of variants

Journal of Experimental Medicine (2021) 218(5)
DOI: 10.1084/jem.20210198
10Citations
Citations of this article
25Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Christos Kyratsous, Vice President of Research, Infectious Diseases, and Viral Vector Technologies at Regeneron Pharmaceuticals, and Alina Baum, Associate Director, Infectious Diseases Associate at Regeneron Pharmaceuticals, discuss the development of antibody therapeutics targeting the spike protein of SARS-CoV-2.

Cite

CITATION STYLE

APA

Baum, A., & Kyratsous, C. A. (2021). SARS-CoV-2 spike therapeutic antibodies in the age of variants. Journal of Experimental Medicine, 218(5). https://doi.org/10.1084/jem.20210198

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free